fluconazole has been researched along with Granulomatosis with Polyangiitis in 1 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Granulomatosis with Polyangiitis: A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cryptococcosis is the third most common invasive fungal infection in organ transplant recipients after candidiasis and aspergillosis." | 1.33 | Intracranial granuloma and skull osteolysis: complication of a primary cutaneous cryptococcosis in a kidney transplant recipient. ( Aldigier, JC; Diaconita, M; Le Meur, Y; Paraf, F; Rerolle, JP; Szelag, JC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rerolle, JP | 1 |
| Szelag, JC | 1 |
| Diaconita, M | 1 |
| Paraf, F | 1 |
| Aldigier, JC | 1 |
| Le Meur, Y | 1 |
1 other study available for fluconazole and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Intracranial granuloma and skull osteolysis: complication of a primary cutaneous cryptococcosis in a kidney transplant recipient.
Topics: Abscess; Amphotericin B; Animals; Antifungal Agents; Combined Modality Therapy; Cryptococcosis; Debr | 2005 |